-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Stoke Therapeutics, Lowers Price Target to $35

Benzinga·05/14/2025 17:51:21
Listen to the news
HC Wainwright & Co. analyst Andrew Fein maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $47 to $35.